While Elevidys was previously approved under accelerated approval for ambulatory individuals 4 through 5 years with a confirmed mutation in the DMD gene, Thursday’s expanded approval includes ambulatory and non-ambulatory patients 4 years of age and older with a confirmed mutation in the DMD gene.
Zealand Pharma on Thursday posted interim Phase Ib data for its investigational amylin analog petrelintide, touting strong weight reduction and a favorable tolerability profile.
Jazz Pharmaceuticals on Thursday reported that its investigational calcium channel modulator suvecaltamide missed its primary endpoint in a Phase IIb study, unable to significantly improve symptoms in patients with essential tremor.
Britain’s National Health Service said on Friday it was investigating claims that hackers had published confidential data stolen from several London hospitals in a cyber attack on a blood testing lab.
The World Health Organization (WHO) on Thursday issued warnings on falsified semaglutides used in diabetes and weight-loss drugs in light of three altered batches of products detected in Brazil, the UK, and the United States.
A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.